Log In
Print
BCIQ
Print
Print this Print this
 

basiliximab (Simulect)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionChimeric antibody against interleukin-2 (IL-2) receptor on activated T cells
Molecular Target Interleukin-2 (IL-2) receptor
Mechanism of ActionBinds interleukin-2 (IL-2) receptor
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today